The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy

Monaldi Arch Chest Dis. 2018 Sep 5;88(3):975. doi: 10.4081/monaldi.2018.975.

Abstract

Hormonal abnormalities are quite common in chronic heart failure (CHF). The most studied hormonal axis in CHF is the impairment of Growth Hormone (GH)/Insulin Growth Factor-1(IGF-1), which in turn is defined either by a blunted response to GH stimulation test or low serum IGF-1 values. Several independent groups reported that the presence of an abnormal GH/IGF-1 status in CHF is associated with a more severe disease, impaired functional capacity and reduced Survival rates. After the first encouraging results, double -blind controlled trials showed a neutral effect of the GH administration in patients. However, further studies reported positive results, when a GH-therapy is implemented only in those patients presenting a GH deficiency (replacement therapy).

Keywords: Chronic heart failure; IGF-1; anabolic deficiency; biomarker; growth hormone; outcomes..

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Heart Failure / drug therapy
  • Heart Failure / metabolism*
  • Human Growth Hormone / metabolism*
  • Human Growth Hormone / therapeutic use
  • Humans
  • Insulin-Like Growth Factor I / metabolism*

Substances

  • Human Growth Hormone
  • Insulin-Like Growth Factor I